These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 39311094)

  • 1. Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.
    Hori M; Hayama-Terada M; Kitamura A; Hosozawa M; Muto Y; Iba A; Takayama Y; Kimura T; Iso H
    J Med Virol; 2024 Sep; 96(9):e29928. PubMed ID: 39311094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk factors of post-coronavirus disease 2019 condition among children and adolescents in Japan: A matched case-control study in the general population.
    Hosozawa M; Hori M; Hayama-Terada M; Arisa I; Muto Y; Kitamura A; Takayama Y; Iso H
    Int J Infect Dis; 2024 Jun; 143():107008. PubMed ID: 38484930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and Risk Factors for Post-COVID-19 Condition during Omicron BA.5-Dominant Wave, Japan.
    Iba A; Hosozawa M; Hori M; Muto Y; Muraki I; Masuda R; Tamiya N; Iso H
    Emerg Infect Dis; 2024 Jul; 30(7):1380-1389. PubMed ID: 38916571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Long SARS-CoV-2 Omicron Infection on the Health Care Burden: Comparative Case-Control Study Between Omicron and Pre-Omicron Waves.
    Valdivieso-Martinez B; Lopez-Sanchez V; Sauri I; Diaz J; Calderon JM; Gas-Lopez ME; Lidon L; Philibert J; Lopez-Hontangas JL; Navarro D; Cuenca L; Forner MJ; Redon J
    JMIR Public Health Surveill; 2024 Sep; 10():e53580. PubMed ID: 39226091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
    Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M
    Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study.
    Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ
    Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postacute symptoms 4 months after SARS-CoV-2 infection during the Omicron period: a nationwide Danish questionnaire study.
    Spiliopoulos L; Sørensen AIV; Bager P; Nielsen NM; Hansen JV; Koch A; Meder IK; Videbech P; Ethelberg S; Hviid A
    Am J Epidemiol; 2024 Aug; 193(8):1106-1114. PubMed ID: 37981717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between SARS-CoV-2 variants and post COVID-19 condition: findings from a longitudinal cohort study in the Belgian adult population.
    Thi Khanh HN; Cornelissen L; Castanares-Zapatero D; De Pauw R; Van Cauteren D; Demarest S; Drieskens S; Devleesschauwer B; De Ridder K; Charafeddine R; Smith P
    BMC Infect Dis; 2023 Nov; 23(1):774. PubMed ID: 37940843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection.
    Malden DE; Liu IA; Qian L; Sy LS; Lewin BJ; Asamura DT; Ryan DS; Bezi C; Williams JTB; Kaiser R; Daley MF; Nelson JC; McClure DL; Zerbo O; Henninger ML; Fuller CC; Weintraub ES; Saydah S; Tartof SY
    Nat Commun; 2024 May; 15(1):4101. PubMed ID: 38778026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts.
    Ballouz T; Menges D; Kaufmann M; Amati R; Frei A; von Wyl V; Fehr JS; Albanese E; Puhan MA
    PLoS One; 2023; 18(2):e0281429. PubMed ID: 36812215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO).
    Mikolajczyk R; Diexer S; Klee B; Pfrommer L; Purschke O; Fricke J; Ahnert P; Gabrysch S; Gottschick C; Bohn B; Brenner H; Buck C; Castell S; Gastell S; Greiser KH; Harth V; Heise JK; Holleczek B; Kaaks R; Keil T; Krist L; Leitzmann M; Lieb W; Meinke-Franze C; Michels KB; Velásquez IM; Obi N; Panreck L; Peters A; Pischon T; Schikowski T; Schmidt B; Standl M; Stang A; Völzke H; Weber A; Zeeb H; Karch A
    J Infect; 2024 Aug; 89(2):106206. PubMed ID: 38897239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
    Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
    Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of BNT162b2 Vaccine Against Symptomatic SARS-CoV-2 Infection in Children Aged 5-11 Years in Japan During Omicron Variant Predominate Periods.
    Hara M; Ohta Y; Fusazaki N; Hirota Y
    J Epidemiol; 2024 May; 34(5):205-210. PubMed ID: 37460294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort.
    Wee LE; Lim JT; Tay AT; Chiew CJ; Ong B; Lye DCB; Lahiri M; Tan KB
    JAMA Netw Open; 2024 Aug; 7(8):e2430983. PubMed ID: 39212988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination status and disease severity of COVID-19 in different phases of the pandemic.
    Yang X; Shi F; Zhang J; Gao H; Chen S; Olatosi B; Weissman S; Li X
    Hum Vaccin Immunother; 2024 Dec; 20(1):2353491. PubMed ID: 38832632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.